Australia explains rules for risk management plans
This article was originally published in SRA
Drug companies in Australia are being advised to discuss with the Therapeutic Goods Administration the need for a risk management plan when they are planning their registration dossiers for certain types of prescription medicines1. The move is part of a new TGA initiative that requires RMPs to be submitted for applications for new chemical entities and significant extensions of indications, for example.
You may also be interested in...
Companies are being encouraged to become “early adopters” of the EU Clinical Trials Information System when it goes live in December 2021.
Drug companies will be able to “play around” with the new EU Clinical Trials Information System in a secure testing environment before it goes live in approximately 15 months.
The Canadian authorities have put in place an expedited pathway for authorizing new COVID-19 drugs and vaccines that offers a more agile approach to reviewing data than what was previously allowed.